



## Structural and Computational-Driven Molecule Design in Drug Discovery

Guest Editors:

**Dr. Halil İbrahim Ciftci**

**Dr. Belgin Sever**

**Dr. Hasan Demirci**

Deadline for manuscript  
submissions:

**closed (26 February 2024)**

### Message from the Guest Editors

Drug development is a complicated, high-risk, expensive, and lengthy process along with several stages such as target identification, lead discovery and lead optimization. In this process, the congruence between computational and experimental outcomes is a mainstay for the exploration of novel compounds. Besides, in the drug development process, many drug candidates could not pass the trials successfully due to the inadequate ADMET properties. Therefore, in silico ADMET analysis is attractive and a cost-saving strategy for a large number of compounds prior to applying expensive and time-consuming in vitro and in vivo ADMET estimation.

This Special Issue aims to provide deep mechanistic insights into strategies in structural dynamics studies and computational methods. It is our great pleasure to invite you to submit original research articles and reviews in a Special Issue on “Structural and Computational-Driven Molecule Design in Drug Discovery”. Research areas may include (but are not limited to) the following: Structural dynamics studies Computer-aided drug design Molecular dynamics simulations Molecular docking Virtual screening QSAR In silico ADMET.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)